143 Measuring pcr/atp as a marker of myocardial energetics across the spectrum of metabolic cardiac disease. (6th June 2022)
- Record Type:
- Journal Article
- Title:
- 143 Measuring pcr/atp as a marker of myocardial energetics across the spectrum of metabolic cardiac disease. (6th June 2022)
- Main Title:
- 143 Measuring pcr/atp as a marker of myocardial energetics across the spectrum of metabolic cardiac disease
- Authors:
- Henry, John Aaron
Levelt, Eylem
Rayner, Jenny
Hundertmark, Moritz
Peterzan, Mark
Green, Peregrine
Watson, William
Lewis, Andrew
Burrage, Matthew
Arvidsson, Per
Chamley, Rebecca
Nicol, Ed
Holdsworth, David
Neubauer, Stefan
Valkovic, Ladislav
Rider, Oliver - Abstract:
- Abstract : Introduction: Derangements in myocardial energetics are thought to play an important role in the pathophysiology of several cardiac diseases. Myocardial energetics can non-invasively be assessed by measuring the phosphocreatine-to-adenosine triphosphate ratio (PCr/ATP) using 31Phosphorus magnetic resonance spectroscopy (31P-MRS). Here we compare cardiac PCr/ATP across a spectrum of metabolic cardiac pathologies. MethodsUsing a 3D chemical shift imaging sequence and surface coil we recorded PCr/ATP in 433 participants: athletes (n=17), healthy controls with normal weight (n=148), overweight (n=67) and with obesity (n=73), diabetes (n=23), heart failure with preserved ejection fraction (HFpEF) (n=33), heart failure with reduced ejection fraction (HFrEF) (n=63) and amyloid (n=9). Results: A spectrum of myocardial PCr/ATP exists ranging from normal in athletes (2.23 ± 0.28) and those with normal weight (2.05 ± 0.38) to severely impaired in those with cardiac amyloid (1.34 ± 0.19, Figure 1). Despite normal systolic function (all LVEF >57%) those living with obesity and diabetes have lower PCr/ATP than normal (all p<0.001). In all groups with HF, regardless of aetiology, myocardial energetics were impaired (all p<0.001). Across the whole cohort PCr/ATP was negatively correlated with body mass index (r -0.28, p <0.001), age (r -0.34, p<0.001) and LV mass (r -0.1, p<0.001). PCr/ATP was not related to systolic or diastolic blood pressure in these cohorts. Conclusions:Abstract : Introduction: Derangements in myocardial energetics are thought to play an important role in the pathophysiology of several cardiac diseases. Myocardial energetics can non-invasively be assessed by measuring the phosphocreatine-to-adenosine triphosphate ratio (PCr/ATP) using 31Phosphorus magnetic resonance spectroscopy (31P-MRS). Here we compare cardiac PCr/ATP across a spectrum of metabolic cardiac pathologies. MethodsUsing a 3D chemical shift imaging sequence and surface coil we recorded PCr/ATP in 433 participants: athletes (n=17), healthy controls with normal weight (n=148), overweight (n=67) and with obesity (n=73), diabetes (n=23), heart failure with preserved ejection fraction (HFpEF) (n=33), heart failure with reduced ejection fraction (HFrEF) (n=63) and amyloid (n=9). Results: A spectrum of myocardial PCr/ATP exists ranging from normal in athletes (2.23 ± 0.28) and those with normal weight (2.05 ± 0.38) to severely impaired in those with cardiac amyloid (1.34 ± 0.19, Figure 1). Despite normal systolic function (all LVEF >57%) those living with obesity and diabetes have lower PCr/ATP than normal (all p<0.001). In all groups with HF, regardless of aetiology, myocardial energetics were impaired (all p<0.001). Across the whole cohort PCr/ATP was negatively correlated with body mass index (r -0.28, p <0.001), age (r -0.34, p<0.001) and LV mass (r -0.1, p<0.001). PCr/ATP was not related to systolic or diastolic blood pressure in these cohorts. Conclusions: Despite normal systolic function, overweight, obesity and diabetes are associated with lower PCr/ATP ratios than normal weight controls. These changes in myocardial energetics appear to exist on a spectrum with further derangement present in overt cardiac pathology. Derangements in myocardial energetics are present in myocardial pathologies independent of underlying aetiology and thus may represent a viable therapeutic target in several conditions. Conflict of Interest: None … (more)
- Is Part Of:
- Heart. Volume 108(2022)Supplement 1
- Journal:
- Heart
- Issue:
- Volume 108(2022)Supplement 1
- Issue Display:
- Volume 108, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 108
- Issue:
- 1
- Issue Sort Value:
- 2022-0108-0001-0000
- Page Start:
- A109
- Page End:
- A110
- Publication Date:
- 2022-06-06
- Subjects:
- Energetics -- Spectroscopy -- PCr/ATP
Heart -- Diseases -- Treatment -- Periodicals
Cardiology -- Periodicals
616.12 - Journal URLs:
- http://www.bmj.com/archive ↗
http://heart.bmj.com ↗
http://www.heartjnl.com ↗ - DOI:
- 10.1136/heartjnl-2022-BCS.143 ↗
- Languages:
- English
- ISSNs:
- 1355-6037
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21940.xml